IMM Immupharma Plc

    RNS Number : 2381U
  Immupharma PLC
  13 May 2008
   


 For Immediate Release  13 May 2008


        
    ImmuPharma PLC

    Lupus drug candidate IPP-201101 obtains trademark LUPUZOR TM 


ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces today that it
received approval of its trademark name LUPUZOR TM for its lead drug candidate for Lupus IPP-201101, by the US Patent and Trademark Office.
 

    Immupharma has selected the trademark LUPUZOR TM for use in association with its peptide therapy for treating immunological disorders,
including systemic lupus erythematosus (SLE). An application for reserving the right to use the LUPUZOR TM trademark was filed, and has now
been allowed by the United States Patent and Trademark Office (Serial No. 77239130).
    
Dimitri Dimitriou, ImmuPharma*s CEO commented: *We believe LUPUZOR TM is a milestone in preparing for the commercialisation of our lead drug
candidate for Lupus. The LUPUZOR TM brand will potentially facilitate the rapid market uptake of the compound by enabling a strong awareness
from patients, physicians and healthcare organisations.*
 
LUPUZOR TM is currently undergoing a large Phase IIb clinical trial in Lupus patients in Europe and Latin America, results of which are
expected later this year. LUPUZOR TM has already shown efficacy and safety in a small Phase II study in late 2006. LUPUZOR TM may reach the
market in around two and a half years* time, providing substantial revenues for the company.


    For further information please contact: 

 ImmuPharma PLC:                                                          
 Dimitri Dimitriou, Chief Executive Officer              +44 20 7152 4080
 Dr Robert Zimmer, President & Chief Scientific Officer  + 33 389 32 76 50
 Richard Warr, Chairman                                  +44 20 7152 4080
                                                                          
 Buchanan Communications                                 + 44 20 7466 5000
 Lisa Baderoon                                                            
 Rebecca Skye Dietrich                                                    
                                                                          
 Panmure Gordon & Co                                                      
 Andrew Burnett                                          +44 151 243 0963



    For company information, visit www.immupharma.com


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
MSCFKBKQPBKDNPD

Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024

Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024